Prospective validation of 18F-FDG brain PET discriminant analysis methods in the diagnosis of amyotrophic lateral sclerosis

Journal of Nuclear Medicine

Volumn 57, Issue 8, 2016, Pages 1238-1243

  Van Weehaeghe, Donatienne ^a   Ceccarini, Jenny ^a   Delva, Aline ^a   Robberecht, Wim ^a,b   Van Damme, Philip ^a,b,c   Van Laere, Koen ^a  

^a UNIVERSITY HOSPITALS LEUVEN   (Belgium)

^b UNIVERSITY OF LEUVEN   (Belgium)

^c DEPARTMENT OF PLANT SYSTEMS BIOLOGY   (Belgium)

Author keywords

ALS; Discriminant analysis; PET; Prognosis; Support vector machine

Indexed keywords

FLUORODEOXYGLUCOSE F 18; RADIOPHARMACEUTICAL AGENT;

ADULT; AGE DISTRIBUTION; AMYOTROPHIC LATERAL SCLEROSIS; ARTICLE; BRAIN METABOLISM; BRAIN REGION; CONTROLLED STUDY; DIAGNOSTIC ACCURACY; DISEASE DURATION; FEMALE; HUMAN; IMAGE ANALYSIS; MAJOR CLINICAL STUDY; MALE; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; PROGNOSIS; PROGRESSIVE MUSCULAR ATROPHY; PROSPECTIVE STUDY; SEX DIFFERENCE; SUPPORT VECTOR MACHINE; SURVIVAL RATE; VALIDATION STUDY; VOXEL BASED MORPHOMETRY; AUTOMATED PATTERN RECOGNITION; BRAIN; COMPUTER ASSISTED DIAGNOSIS; COMPUTER SIMULATION; DIAGNOSTIC IMAGING; DISCRIMINANT ANALYSIS; EVALUATION STUDY; IMAGE ENHANCEMENT; MIDDLE AGED; PROCEDURES; REPRODUCIBILITY; SENSITIVITY AND SPECIFICITY; STATISTICAL ANALYSIS; STATISTICAL MODEL; THREE DIMENSIONAL IMAGING;

AMYOTROPHIC LATERAL SCLEROSIS; BRAIN; COMPUTER SIMULATION; DATA INTERPRETATION, STATISTICAL; DISCRIMINANT ANALYSIS; FEMALE; FLUORODEOXYGLUCOSE F18; HUMANS; IMAGE ENHANCEMENT; IMAGE INTERPRETATION, COMPUTER-ASSISTED; IMAGING, THREE-DIMENSIONAL; MALE; MIDDLE AGED; MODELS, STATISTICAL; PATTERN RECOGNITION, AUTOMATED; POSITRON-EMISSION TOMOGRAPHY; PROSPECTIVE STUDIES; RADIOPHARMACEUTICALS; REPRODUCIBILITY OF RESULTS; SENSITIVITY AND SPECIFICITY;

EID: 84982847674     PISSN: 01615505     EISSN: 2159662X     Source Type: Journal    
DOI: 10.2967/jnumed.115.166272     Document Type: Article

References (34)

1. Rowland LP, Shneider NA. Amyotrophic lateral sclerosis. N Engl J Med. 2001;344:1688-1700.
2. Quartuccio N, Van Weehaeghe D, Cistaro A, Jonsson C, Van Laere K, Pagani M. Positron emission tomography neuroimaging in amyotrophic lateral sclerosis: what is new? Q J Nucl Med Mol Imaging. 2014;58:344-354.
3. Renton AE, Chio A, Traynor BJ. State of play in amyotrophic lateral sclerosis genetics. Nat Neurosci. 2014;17:17-23.
4. Van Laere K, Vanhee A, Verschueren J, et al. Value of 18fluorodeoxyglucose-positron-emission tomography in amyotrophic lateral sclerosis: a prospective study. JAMA Neurol. 2014;71:553-561.
5. Costa J, Swash M, de Carvalho M. Awaji criteria for the diagnosis of amyotro-phic lateral sclerosis:a systematic review. Arch Neurol. 2012;69:1410-1416.
6. Schrooten M, Smetcoren C, Robberecht W, Van Damme P. Benefit of the Awaji diagnostic algorithm for amyotrophic lateral sclerosis: a prospective study. Ann Neurol. 2011;70:79-83.
7. Cistaro A, Cuccurullo V, Quartuccio N, Pagani M, Valentini MC, Mansi L. Role of PET and SPECT in the study of amyotrophic lateral sclerosis. Biomed Res Int. 2014;2014:237437.
8. Dalakas MC, Hatazawa J, Brooks RA, Di Chiro G. Lowered cerebral glucose utilization in amyotrophic lateral sclerosis. Ann Neurol. 1987;22:580-586.
9. Ludolph AC, Langen KJ, Regard M, et al. Frontal lobe function in amyotrophic lateral sclerosis: a neuropsychologic and positron emission tomography study. Acta Neurol Scand. 1992;85:81-89.
10. Pagani M, Chio A, Valentini MC, et al. Functional pattern of brain FDG-PET in amyotrophic lateral sclerosis. Neurology. 2014;83:1067-1074.
11. Pringle CE, Hudson AJ, Munoz DG, Kiernan JA, Brown WF, Ebers GC. Primary lateral sclerosis: clinical features, neuropathology and diagnostic criteria. Brain. 1992;115:495-520.
12. Cistaro A, Valentini MC, Chio A, et al. Brain hypermetabolism in amyotrophic lateral sclerosis: a FDG PET study in ALS of spinal and bulbar onset. Eur J Nucl Med Mol Imaging. 2012;39:251-259.
13. Corcia P, Tauber C, Vercoullie J, et al. Molecular imaging of microglial activation in amyotrophic lateral sclerosis. PLoS One. 2012;7:e52941.
14. 11C](R)-PK11195 positron emission tomography study. Neurobiol Dis. 2004;15:601-609.
15. Foerster BR, Dwamena BA, Petrou M, et al. Diagnostic accuracy of diffusion tensor imaging in amyotrophic lateral sclerosis: a systematic review and individual patient data meta-analysis. Acad Radiol. 2013;20:1099-1106.
16. Pradat PF, El Mendili MM. Neuroimaging to investigate multisystem involvement and provide biomarkers in amyotrophic lateral sclerosis. Biomed Res Int. 2014;2014:467560.
17. Foerster BR, Carlos RC, Dwamena BA, et al. Multimodal MRI as a diagnostic biomarker for amyotrophic lateral sclerosis. Ann Clin Transl Neurol. 2014;1: 107-114.
18. Filippini N, Douaud G, Mackay CE, Knight S, Talbot K, Turner MR. Corpus callosum involvement is a consistent feature of amyotrophic lateral sclerosis. Neurology. 2010;75:1645-1652.
19. Chiò A, Ilardi A, Cammarosano S, Moglia C, Montuschi A, Calvo A. Neuro-behavioral dysfunction in ALS has a negative effect on outcome and use of PEG and NIV. Neurology. 2012;78:1085-1089.
20. Elamin M, Bede P, Byrne S, et al. Cognitive changes predict functional decline in ALS: a population-based longitudinal study. Neurology. 2013;80:1590-1597.
21. 18F-flutemetamol PET using machine learning: comparison with visual reads and structural MRI. Neuroimage. 2013;64:517-525.
22. Abrahams S, Goldstein LH, Kew JJ, et al. Frontal lobe dysfunction in amyotro-phic lateral sclerosis: a PET study. Brain. 1996;119:2105-2120.
23. Fatima M, Tan R, Halliday GM, Kril JJ. Spread of pathology in amyotrophic lateral sclerosis: assessment of phosphorylated TDP-43 along axonal pathways. Acta Neuropathol Commun. 2015;3:47-55.
24. Kassubek J, Muller HP, Del Tredici K, et al. Diffusion tensor imaging analysis of sequential spreading of disease in amyotrophic lateral sclerosis confirms patterns of TDP-43 pathology. Brain. 2014;137:1733-1740.
25. 18F]fluoro-deoxyglucose PET discriminates MCI converting to Alzheimer's disease from healthy controls: a European Alzheimer's Disease Consortium (EADC) study. Neuroimage Clin. 2014;7:34-42.
26. Dukart J, Mueller K, Barthel H, et al. Meta-analysis based SVM classification enables accurate detection of Alzheimer's disease across different clinical centers using FDG-PET and MRI. Psychiatry Res. 2013;212:230-236.
27. Tahmasian M, Shao J, Meng C, et al. Based on the network degeneration hypothesis: separating individual patients with different neurodegenerative syndromes in a preliminary hybrid PET/MR study. J Nucl Med. 2016;57: 410-415.
28. Irwin DJ, McMillan CT, Brettschneider J, et al. Cognitive decline and reduced survival in C9orf72 expansion frontotemporal degeneration and amyotrophic lateral sclerosis. J Neurol Neurosurg Psychiatry. 2013;84:163-169.
29. Agosta F, Gorno-Tempini ML, Pagani E, et al. Longitudinal assessment of grey matter contraction in amyotrophic lateral sclerosis: a tensor based morphometry study. Amyotroph Lateral Scler. 2009;10:168-174.
30. Chang JL, Lomen-Hoerth C, Murphy J, et al. A voxel-based morphometry study of patterns of brain atrophy in ALS and ALS/FTLD. Neurology. 2005;65:75-80.
31. Grosskreutz J, Kaufmann J, Fradrich J, Dengler R, Heinze HJ, Peschel T. Widespread sensorimotor and frontal cortical atrophy in amyotrophic lateral sclerosis. BMC Neurol. 2006;6:17-26.
32. Tsujimoto M, Senda J, Ishihara T, et al. Behavioral changes in early ALS correlate with voxel-based morphometry and diffusion tensor imaging. J Neurol Sci. 2011;307:34-40.
33. Bede P, Hardiman O. Lessons of ALS imaging: pitfalls and future directions-a critical review. Neuroimage Clin. 2014;4:436-443.
34. Turner MR, Wicks P, Brownstein CA, et al. Concordance between site of onset and limb dominance in amyotrophic lateral sclerosis. J Neurol Neurosurg Psychiatry. 2011;82:853-854.